Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

05 Mar 2017 - 09 Mar 2017
20 Mar 2017 - 23 Mar 2017
12 Apr 2017 - 14 Apr 2017

Single Gene Mutation Linked to Development of Type II Diabetes

By BiotechDaily International staff writers
Posted on 14 Jan 2014
Image: A mouse pancreatic islet as seen by light microscopy. Beta cells can be recognized by the green insulin staining (Photo courtesy of Wikimedia Commons).
Image: A mouse pancreatic islet as seen by light microscopy. Beta cells can be recognized by the green insulin staining (Photo courtesy of Wikimedia Commons).
ADVERTISEMENT
SARTORIUS AG
Diabetes researchers working with a genetically engineered mouse model have identified a mutation in a single gene that has potential for being a therapeutic target for type II diabetes.

Type II diabetes, which is characterized by disruption in the activity of pancreatic beta-cells with subsequent loss of sensitivity to insulin, affects more than 366 million people worldwide and can cause serious complications including cardiovascular disease, kidney failure, loss of limbs, and blindness.

Investigators at the University of Illinois Chicago College of Medicine (USA) had shown previously that the IG20/MADD (MAP kinase-activating death domain protein) gene was linked to beta-cell function in an unknown fashion.

To study this linkage further, the investigators genetically engineered a line of mice that lacked the MADD gene in their insulin-producing beta cells. Results published in the December 30, 2013, online edition of the journal Diabetes revealed that these animals displayed the hyperglycemia and glucose intolerance associated with reduced and delayed glucose-induced insulin production. Beta cells from these animals were able to process insulin normally, but had increased insulin accumulation and showed a severe defect in glucose-induced insulin release.

These findings indicated that IG20/MADD played a critical role in glucose-induced insulin release from beta cells and its functional disruption could cause type II diabetes.

Referring to the genetically engineered mice, senior author Dr. Bellur S. Prabhakar, professor of microbiology and immunology at the University of Illinois Chicago College of Medicine, said that, “We did not see any insulin resistance in their cells, but it was clear that the beta-cells were not functioning properly. Examination of the beta cells revealed that they were packed with insulin. The cells were producing plenty of insulin; they just were not secreting it. If a drug that allows for the secretion of insulin in MADD-deficient beta cells works to reverse the deficits associated with a defective MADD gene in the beta cells of our model mice, it may have potential for treating people with this mutation who have an insulin-secretion defect and/or type II diabetes.”

Related Links:

University of Illinois Chicago College of Medicine



Channels

Drug Discovery

view channel
Image: The experimental drug NGI-1 slows cancer growth by blocking glycosylation of the epidermal growth factor receptor (EGFR), which is shown in the above diagram (Photo courtesy of Wikimedia Commons).

Experimental Drug Slows Lung Cancer Growth by Blocking Protein Glycosylation

An interesting new experimental anti-cancer drug slows growth of certain lung tumor cells by preventing the glycosylation of critical cell surface receptor proteins. Asparagine (N)-linked glycosylation... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.